Etiology of Parkinson's Disease
暂无分享,去创建一个
A. Jon Stoessl | A. Stoessl | R. Fuente-Fernández | Zhigao Huang | Raúl de la Fuente-Fernández | Zhigao Huang
[1] R. Duvoisin,et al. Dopaminergic toxicity after the stereotaxic administration of the 1-methyl-4-phenylpyridinium ion (MPP+) to rats , 1985, Neuroscience Letters.
[2] J. Trojanowski,et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.
[3] M. Beal,et al. Aging, energy, and oxidative stress in neurodegenerative diseases , 1995, Annals of neurology.
[4] A. Cools,et al. Neurorescuing effects of the GAPDH ligand CGP 3466B. , 2000, Journal of neural transmission. Supplementum.
[5] K Teschke,et al. Occupational and environmental risk factors for Parkinson's disease. , 2002, Parkinsonism & related disorders.
[6] M Barinaga,et al. Death by Dozens of Cuts , 1998, Science.
[7] M G Spillantini,et al. Alpha-synuclein in Lewy bodies. , 1997, Nature.
[8] A. Barzilai,et al. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons — A possible novel pathogenetic mechanism in Parkinson's disease , 1994, Neuroscience Letters.
[9] P. Vieregge,et al. Long Term Exposure to Manganese in Rural Well Water Has No Neurological Effects , 1995, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[10] J. Labandeira-Garcia,et al. Autoxidation and Neurotoxicity of 6‐Hydroxydopamine in the Presence of Some Antioxidants , 2000, Journal of neurochemistry.
[11] S. Melov,et al. Mitochondrial DNA mutations, oxidative stress, and aging , 2001, Mechanisms of Ageing and Development.
[12] N. Volkow,et al. Inhibition of monoamine oxidase B in the brains of smokers , 1996, Nature.
[13] Strang Rr. The etiology of Parkinson's disease. , 1970, Diseases of the nervous system.
[14] H Checkoway,et al. Dietary factors in Parkinson's disease: The role of food groups and specific foods , 1999, Movement disorders : official journal of the Movement Disorder Society.
[15] I. Ceballos-Picot,et al. Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: relevance to Parkinson's disease. , 1998, Biochemical pharmacology.
[16] Dallas W. Anderson,et al. Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississippi , 1985, Neurology.
[17] E. Zamrini,et al. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. , 1997, The American journal of pathology.
[18] B. Müller-Myhsok,et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13 , 1998, Nature Genetics.
[19] G. Defazio,et al. Parkinsonian serum carries complement-dependent toxicity for rat mesencephalic dopaminergic neurons in culture , 1994, Brain Research.
[20] J. Gorell,et al. Environmental Risk Factors for Parkinson's Disease , 2003 .
[21] P. Riederer,et al. The possible role of iron in the etiopathology of parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.
[22] Y. Agid. Levodopa: Is toxicity a myth? , 1998, Neurology.
[23] J. Haines,et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.
[24] F. Cheng,et al. Inhibitors of Mitochondrial Respiration, Iron (II), and Hydroxyl Radical Evoke Release and Extracellular Hydrolysis of Glutathione in Rat Striatum and Substantia Nigra , 1999, Journal of neurochemistry.
[25] D. Calne,et al. Evidence for environmental causation of Parkinson's disease. , 2002, Parkinsonism & related disorders.
[26] A. Bentivoglio,et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. , 2001, American journal of human genetics.
[27] P. Sonsalla,et al. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium. , 1994, The Journal of pharmacology and experimental therapeutics.
[28] V. Davila,et al. Neurotrophic Effects of l‐DOPA in Postnatal Midbrain Dopamine Neuron/Cortical Astrocyte Cocultures , 1997, Journal of neurochemistry.
[29] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[30] FRCPtt A. E. Harding,et al. Nigrostriatal function in vitamin E deficiency: Clinical, experimental, and positron emission tomographic studies , 1994, Annals of neurology.
[31] C. Marsden,et al. Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1995, Biochemical pharmacology.
[32] S. Kish,et al. Aging Produces a Specific Pattern of Striatal Dopamine Loss: Implications for the Etiology of Idiopathic Parkinson's Disease , 1992, Journal of neurochemistry.
[33] H. Yoshino,et al. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease , 1992, Journal of neural transmission. Parkinson's disease and dementia section.
[34] L. Fleming,et al. Parkinson's disease and brain levels of organochlorine pesticides , 1994, Annals of neurology.
[35] E. Hirsch,et al. Increased m-calpain expression in the mesencephalon of patients with parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? , 1996, Neuroscience.
[36] A. Schapira,et al. Mitochondrial respiratory chain disorders II: neurodegenerative disorders and nuclear gene defects , 2000, The Lancet.
[37] M. Yahr,et al. Postencephalitic parkinsonism – a review , 1998, Journal of Neural Transmission.
[38] B. Jenkins,et al. Dopamine imaging markers and predictive mathematical models for progressive degeneration in Parkinson's disease. , 1999, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[39] O. Axelson,et al. Nutritional and occupational factors influencing the risk of Parkinson's disease: A case‐control study in southeastern Sweden , 1999, Movement disorders : official journal of the Movement Disorder Society.
[40] Y. Agid. [Aging, disease and nerve cell death]. , 1995, Bulletin de l'Academie nationale de medecine.
[41] S E Ide,et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.
[42] R A Crowther,et al. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[43] M. Fishman,et al. Prevention of vertebrate neuronal death by the crmA gene. , 1994, Science.
[44] J. Gusella,et al. Genetic linkage studies in autosomal dominant parkinsonism: Evaluation of seven candidate genes , 1994, Annals of neurology.
[45] S. Dimauro,et al. Mitochondria1 involvement in Parkinson's disease , 1993, Neurology.
[46] M. Nielsen,et al. Caspase-mediated Parkin Cleavage in Apoptotic Cell Death* , 2002, The Journal of Biological Chemistry.
[47] D. Schroeder,et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease , 1996, Neurology.
[48] B. Shastry,et al. Parkinson disease: etiology, pathogenesis and future of gene therapy , 2001, Neuroscience Research.
[49] X M Cheng,et al. A case-control study on the environmental risk factors of Parkinson's disease in Tianjin, China. , 1993, Neuroepidemiology.
[50] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[51] N. Hattori,et al. An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson's disease. , 1994, Annals of Neurology.
[52] C. Marsden,et al. Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration , 2005, Journal of Neural Transmission.
[53] P. Mcgeer,et al. Aging and extrapyramidal function. , 1977, Archives of neurology.
[54] J. Haines,et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. , 2001, JAMA.
[55] R. Uitti,et al. Geography, Drinking Water Chemistry, Pesticides and Herbicides and the Etiology of Parkinson's Disease , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[56] M. Chiba,et al. Mn SOD activity and protein in a patient with chromosome 6-linked autosomal recessive parkinsonism in comparison with Parkinson's disease and control , 1997, Neurology.
[57] C D Marsden,et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.
[58] C. Marsden,et al. Mitochondrial respiratory chain function in multiple system atrophy , 1997, Movement disorders : official journal of the Movement Disorder Society.
[59] R. Uitti,et al. Familial Parkinson's Disease: Possible Role of Environmental Factors , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[60] M. Shelanski,et al. Down-regulation of copper/zinc superoxide dismutase causes apoptotic death in PC12 neuronal cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[61] Harvey Checkoway,et al. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. , 2002, American journal of epidemiology.
[62] M Schulzer,et al. A mathematical model of pathogenesis in idiopathic parkinsonism. , 1994, Brain : a journal of neurology.
[63] Paola Piccini,et al. The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twins , 1999, Annals of neurology.
[64] D. Clayton,et al. Synucleins in synaptic plasticity and neurodegenerative disorders , 1999, Journal of neuroscience research.
[65] K. Marder,et al. Evaluation of 50 probands with early-onset Parkinson’s disease for Parkin mutations , 2002, Neurology.
[66] S. Daniel,et al. Glial pathology but absence of apoptotic nigral neurons in long‐standing Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.
[67] J. Lile,et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.
[68] H. Kimura,et al. Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease , 1993, Neurology.
[69] B. Ritz,et al. Parkinson's disease mortality and pesticide exposure in California 1984-1994. , 2000, International journal of epidemiology.
[70] A. Benabid,et al. Subthalamic Nucleus Lesion in Rats Prevents Dopaminergic Nigral Neuron Degeneration After Striatal 6‐OHDA Injection: Behavioural and Immunohistochemical Studies , 1996, The European journal of neuroscience.
[71] C. Tanner,et al. Association of coffee and caffeine intake with the risk of Parkinson disease. , 2000, JAMA.
[72] S. Minoshima,et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.
[73] L. Olson,et al. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[74] H. Przuntek,et al. Bromocriptine lessens the incidence of mortality in L-Dopa-treated parkinsonian patients: Prado-study discontinued , 2005, European Journal of Clinical Pharmacology.
[75] D. Morens,et al. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. , 1994, American journal of epidemiology.
[76] S. Lipton,et al. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[77] S. Melov,et al. Mitochondrial Oxidative Stress: Physiologic Consequences and Potential for a Role in Aging , 2000, Annals of the New York Academy of Sciences.
[78] J. H. Li,et al. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[79] R. Zivadinov,et al. Familial and environmental risk factors in Parkinson's disease: a case–control study in north‐east Italy , 2002, Acta neurologica Scandinavica.
[80] M. Brin,et al. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.
[81] R. Krüger,et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.
[82] A. Rajput,et al. Frequency and Cause of Parkinson’s Disease , 1992, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[83] H. Chertkow,et al. Absence of mutations in superoxide dismutase and catalase genes in patients with Parkinson's disease. , 1995, Archives of neurology.
[84] D. Calne,et al. AETIOLOGY OF PARKINSON'S DISEASE , 1983, The Lancet.
[85] N. Hattori,et al. An Unfolded Putative Transmembrane Polypeptide, which Can Lead to Endoplasmic Reticulum Stress, Is a Substrate of Parkin , 2001, Cell.
[86] G. Román,et al. Worldwide occurrence of Parkinson's disease: an updated review. , 1993, Neuroepidemiology.
[87] S. Kish,et al. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining , 1997, Neuroscience.
[88] A. J. Bradbury,et al. 1-Methyl-4-phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway , 1986, Nature.
[89] C. Tanner,et al. Absence of mutations in the coding region of the α-synuclein gene in pathologically proven Parkinson's disease , 1998, Neurology.
[90] C. Marsden,et al. New insights into the cause of Parkinson's disease , 1992, Neurology.
[91] J. Riggs,et al. Cigarette smoking and Parkinson disease: the illusion of a neuroprotective effect. , 1992, Clinical neuropharmacology.
[92] Y. Agid,et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. , 1997, Histology and histopathology.
[93] Z. Speiser,et al. Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. , 1998, Journal of neural transmission. Supplementum.
[94] S. Gruber,et al. The epidemiology of Parkinson's disease. A case-control study of young-onset and old-onset patients. , 1991 .
[95] W. Weiner. Parkinson’s Disease and Movement Disorders , 2000, Current Clinical Practice.
[96] D. Perl,et al. A fluorescent double‐labeling method to detect and confirm apoptotic nuclei in parkinson's disease , 1998, Annals of neurology.
[97] Jeffery K. Taubenberger,et al. Initial Genetic Characterization of the 1918 “Spanish” Influenza Virus , 1997, Science.
[98] E. Hirsch,et al. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[99] H. Forman,et al. Glutathione Depletion in PC12 Results in Selective Inhibition of Mitochondrial Complex I Activity , 2000, The Journal of Biological Chemistry.
[100] B. Davidson,et al. Dopaminergic Neurons Protected from Degeneration by GDNF Gene Therapy , 1997, Science.
[101] N. Wood,et al. Genetics of Parkinsonism: a review , 2001, Annals of human genetics.
[102] Y. Agid,et al. Genetic complexity and Parkinson's disease. , 1997, Science.
[103] Y. Agid,et al. Adverse reactions to levodopa: drug toxicity or progression of disease? , 1998, The Lancet.
[104] E. Tolosa,et al. Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. , 1993, Neurology.
[105] Y. Yang,et al. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. , 2000, Neuroscience.
[106] Y. Mizuno,et al. Histochemical detection of apoptosis in Parkinson's disease , 1996, Journal of the Neurological Sciences.
[107] V. Dawson. Neurobiology. Of flies and mice. , 2000, Science.
[108] R. Godwin-Austen,et al. Smoking and Parkinson's disease. , 1982, Journal of neurology, neurosurgery, and psychiatry.
[109] J. Hubble,et al. Risk factors for Parkinson's disease , 1993, Neurology.
[110] T. Dawson,et al. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[111] B J Hoffer,et al. Dopamine neuron agenesis in Nurr1-deficient mice. , 1997, Science.
[112] R. Kalaria,et al. Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[113] P. Maher,et al. A Role for 12-lipoxygenase in Nerve Cell Death Caused by Glutathione Depletion , 1997, Neuron.
[114] A. Rajput. The protective role of levodopa in the human substantia nigra. , 2001, Advances in neurology.
[115] P. Jenner,et al. Understanding cell death in parkinson's disease , 1998, Annals of neurology.
[116] S. Khuder,et al. A meta-analysis of Parkinson's disease and exposure to pesticides. , 2000, Neurotoxicology.
[117] C. Marsden,et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study , 1994, Movement disorders : official journal of the Movement Disorder Society.
[118] A. Schapira,et al. Evidence for mitochondrial dysfunction in Parkinson's disease—a critical appraisal , 2004, Movement disorders : official journal of the Movement Disorder Society.
[119] M. Beal,et al. Caspase-9 Activation Results in Downstream Caspase-8 Activation and Bid Cleavage in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinson's Disease , 2001, The Journal of Neuroscience.
[120] C. Marsden,et al. Complex I, Iron, and ferritin in Parkinson's disease substantia nigra , 1994, Annals of neurology.
[121] A. Lees,et al. Late Progression of Post-Encephalitic Parkinson's Syndrome , 1988, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[122] P. Löschmann,et al. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists , 1991, Nature.
[123] R. G. Lee,et al. Parkinson's disease , 1993, Neurology.
[124] C. C. Johnson,et al. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. , 1999, Neurotoxicology.
[125] H P Ludin,et al. Parkinson's disease in twins , 1992, Neurology.
[126] R. Mayeux,et al. Smoking and Parkinson’s disease in twins , 2002, Neurology.
[127] D. Calne,et al. Occupational risk factors in Parkinson's disease. , 1999, Canadian journal of public health = Revue canadienne de sante publique.
[128] C. Marsden,et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease , 1994, Annals of neurology.
[129] C D Marsden,et al. Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8‐Hydroxyguanine Levels in Substantia Nigra , 1997, Journal of neurochemistry.
[130] R. Swerdlow,et al. Origin and functional consequences of the complex I defect in Parkinson's disease , 1996, Annals of neurology.
[131] E. Teng,et al. A door-to-door survey of Parkinson's disease in a Chinese population in Kinmen. , 1996, Archives of neurology.
[132] J. Nutt,et al. Familial aggregation of Parkinson disease: a comparative study of early-onset and late-onset disease. , 2002, Archives of neurology.
[133] M Schulzer,et al. Clinical observations on the rate of progression of idiopathic parkinsonism. , 1994, Brain : a journal of neurology.
[134] Bruce A. Yankner,et al. Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.
[135] G. Donnan,et al. Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice , 1987, Brain Research.
[136] J W Langston,et al. Parkinson disease in twins: an etiologic study. , 1999, JAMA.
[137] P. Mcgeer,et al. Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.
[138] K. Jellinger. Cell death mechanisms in Parkinson's disease , 2000, Journal of Neural Transmission.
[139] M. Gurney,et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. , 1994, Science.
[140] Y Agid,et al. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[141] K. Jellinger,et al. The enigma of cell death in neurodegenerative disorders. , 2000, Journal of neural transmission. Supplementum.
[142] M. Yen,et al. Prevalence, incidence, and mortality of PD: A door-to-door survey in Ilan County, Taiwan , 2001 .
[143] C. Tzourio,et al. Familial aggregation of Parkinson’s disease , 1999, Neurology.
[144] A. McMahon,et al. Induction of dopaminergic neuron phenotype in the midbrain by Sonic hedgehog protein , 1995, Nature Medicine.
[145] D B Calne,et al. Is idiopathic parkinsonism the consequence of an event or a process? , 1994, Neurology.
[146] Annette M. Schmid,et al. Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones , 1996, Neuroreport.
[147] S. Tsuji,et al. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1 , 2002, Annals of neurology.
[148] M. Goedert,et al. Tau and Parkinson disease. , 2001, JAMA.
[149] Temple F. Smith,et al. Survey of human mitochondrial diseases using new genomic/proteomic tools , 2001, Genome Biology.
[150] A A Hicks,et al. Familial aggregation of Parkinson's disease in Iceland. , 2000, The New England journal of medicine.
[151] Y. Agid,et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions , 1998, Annals of neurology.
[152] J. Nutt,et al. Increased risk of Parkinson's disease in parents and siblings of patients , 1994, Annals of neurology.
[153] J. Kurth,et al. Association of a monoamine oxidase B allele with Parkinson's disease , 1993, Annals of neurology.
[154] R. Uitti,et al. Timely levodopa (LD) administration prolongs survival in Parkinson's disease. , 1997, Parkinsonism & related disorders.
[155] O. Isacson,et al. Neuroinflammation of the nigrostriatal pathway during progressive 6‐OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging , 2002, The European journal of neuroscience.
[156] J. Chen,et al. Reactions of nitric oxide, superoxide and peroxynitrite with superoxide dismutase in neurodegeneration. , 1994, Progress in brain research.
[157] A. Blackburn,et al. Parkinson's disease, pesticides, and glutathione transferase polymorphisms , 1998, The Lancet.
[158] M. Graeber,et al. On the question of apoptosis in the parkinsonian substantia nigra , 1997, Acta Neuropathologica.
[159] C. Carter,et al. Aspirin and Salicylate Protect Against MPTP‐Induced Dopamine Depletion in Mice , 1998, Journal of neurochemistry.
[160] Shelley R. Winn,et al. Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms , 1995, Experimental Neurology.
[161] Dr Ira Shoulson. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa , 1996, Annals of neurology.
[162] F. Vaglini,et al. Nicotine Prevents Experimental Parkinsonism in Rodents and Induces Striatal Increase of Neurotrophic Factors , 1998, Journal of neurochemistry.
[163] L. Olson,et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo , 1995, Nature.
[164] P C O'Brien,et al. Brain injury and neurologic sequelae , 1991, Neurology.
[165] Of Flies and Mice , 2000, Science.
[166] C. C. Johnson,et al. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living , 1998, Neurology.
[167] C. Marsden,et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia , 1994, Annals of neurology.
[168] G. Barja,et al. Deprenyl protects from MPTP-induced Parkinson-like syndrome and glutathione oxidation in rat striatum. , 2002, Toxicology.
[169] C. C. Johnson,et al. Adult nutrient intake as a risk factor for Parkinson's disease. , 1999, International journal of epidemiology.
[170] H. Petrovitch,et al. Current Evidence for Neuroprotective Effects of Nicotine and Caffeine Against Parkinson’s Disease , 2001, Drugs & aging.
[171] D. Calne. The free radical hypothesis in idiopathic parkinsonism: Evidence against it , 1992, Annals of neurology.
[172] J. Nutt,et al. Environmental antecedents of young‐onset Parkinson's disease , 1993, Neurology.
[173] J. Langston,et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure , 1999, Annals of neurology.
[174] M Schulzer,et al. The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic , 1992, Annals of neurology.
[175] R. Vandlen,et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain , 1995, Nature.
[176] M. Schwarzschild,et al. Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson's Disease , 2001, The Journal of Neuroscience.
[177] A. E. Harding,et al. Parkinson's disease in twins studied with 18F‐dopa and positron emission tomography , 1992, Neurology.
[178] J. Schulz,et al. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra , 1997, Brain Research.
[179] Georg Auburger,et al. The ubiquitin pathway in Parkinson's disease , 1998, Nature.
[180] M. Mouradian. Recent advances in the genetics and pathogenesis of Parkinson disease , 2002, Neurology.
[181] J. Mankovich,et al. Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35. , 1995, Science.
[182] M. Naoi,et al. Involvement of endogenous N-methyl(R)salsolinol in Parkinson's disease: induction of apoptosis and protection by (-)deprenyl. , 2000, Journal of neural transmission. Supplementum.
[183] S. Daniel,et al. Glutathione‐related enzymes in brain in Parkinson's disease , 1994, Annals of neurology.
[184] M. Farrer,et al. A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. , 1999, Human molecular genetics.
[185] M. Quik,et al. Nicotinic receptors and Parkinson's disease. , 2000, European journal of pharmacology.
[186] W. Bender,et al. A Drosophila model of Parkinson's disease , 2000, Nature.
[187] M. Spillantini,et al. α‐Synuclein metabolism and aggregation is linked to ubiquitin‐independent degradation by the proteasome , 2001, FEBS letters.
[188] C. Ward,et al. Parkinson's disease in 65 pairs of twins and in a set of quadruplets , 1983, Neurology.
[189] David R. Cox,et al. A potassium channel mutation in weaver mice implicates membrane excitability in granule cell differentiation , 1995, Nature Genetics.
[190] A. Stoessl,et al. Etiology of Parkinson's Disease , 1999, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[191] J. Milbrandt,et al. Neurturin Exerts Potent Actions on Survival and Function of Midbrain Dopaminergic Neurons , 1998, The Journal of Neuroscience.
[192] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[193] A. H. V. Schapira,et al. MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.
[194] S. Shimohama,et al. Methylphenylpyridium ion enhances glutamate-induced cytotoxicity against dopaminergic neurons in cultured rat mesencephalon , 1994 .
[195] Gregory G. Brown,et al. Occupational exposures to metals as risk factors for Parkinson's disease , 1997, Neurology.
[196] M. Naoi,et al. An Endogenous Dopaminergic Neurotoxin, N‐Methyl‐(R)‐Salsolinol, Induces DNA Damage in Human Dopaminergic Neuroblastoma SH‐SY5Y Cells , 1997, Journal of neurochemistry.
[197] D. Morens,et al. Cigarette smoking and protection from Parkinson's disease , 1995, Neurology.
[198] J. Houwing-Duistermaat,et al. Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. , 2001, American journal of human genetics.
[199] W. Tatton,et al. (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. , 1996, Journal of neural transmission. Supplementum.
[200] 高橋 均,et al. Familial juvenile parkinsonism: clinical and pathologic study in afamily , 1993 .
[201] S. Fahn,et al. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.
[202] H. Przuntek,et al. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. , 1991, European journal of pharmacology.
[203] L. Barbeito,et al. Peroxynitrite‐Induced Cytotoxicity in PC12 Cells: Evidence for an Apoptotic Mechanism Differentially Modulated by Neurotrophic Factors , 1995, Journal of neurochemistry.
[204] V. Hachinski,et al. Environmental Exposures in Elderly Canadians With Parkinson’s Disease , 1995, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[205] H. Okada,et al. The substantia nigra is a major target for neurovirulent influenza A virus , 1995, The Journal of experimental medicine.
[206] L. Olson,et al. Neurochemical and Histochemical Characterization of Neurotoxic Effects of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine on Brain Catecholamine Neurones in the Mouse , 1985, Journal of neurochemistry.
[207] A Hartley,et al. Complex I Inhibitors Induce Dose‐Dependent Apoptosis in PC12 Cells: Relevance to Parkinson's Disease , 1994, Journal of neurochemistry.
[208] J. Cooper,et al. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease , 1998, Annals of neurology.
[209] K. Jellinger,et al. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease , 1994, Neuroscience Letters.
[210] Y. Mizuno,et al. bcl-2 Protein is increased in the brain from parkinsonian patients , 1996, Neuroscience Letters.
[211] G. Yancopoulos,et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra , 1991, Nature.
[212] Douglas C. Miller,et al. A large kindred with autosomal dominant Parkinson's disease , 1990, Annals of neurology.
[213] M. Druet‐Cabanac,et al. Parkinson's disease and environmental factors. Matched case-control study in the Limousin region, France. , 2000, Neuroepidemiology.
[214] C. Epstein,et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[215] E. Love,et al. Effects of agricultural work and other proxy-derived case-control data on Parkinson's disease risk estimates. , 1995, American journal of epidemiology.
[216] A. Rajput,et al. Accuracy of Clinical Diagnosis in Parkinsonism — A Prospective Study , 1991, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[217] Raúl de la Fuente‐Fernández. Maternal effect on Parkinson's disease , 2000, Annals of neurology.
[218] C. Tanner,et al. Environmental Factors in the Etiology of Parkinson's Disease , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[219] B. Snow,et al. Isolated involvement of substantia nigra in acute transient parkinsonism: MRI and PET observations. , 1995, Parkinsonism & related disorders.
[220] R. Oppenheim,et al. Peptide inhibitors of the ice protease family arrest programmed cell death of motoneurons in vivo and in vitro , 1995, Neuron.
[221] Nobutaka Hattori,et al. Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease , 2001, Science.